242 related articles for article (PubMed ID: 22357185)
1. Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks.
Diamant M; Van Gaal L; Stranks S; Guerci B; MacConell L; Haber H; Scism-Bacon J; Trautmann M
Diabetes Care; 2012 Apr; 35(4):683-9. PubMed ID: 22357185
[TBL] [Abstract][Full Text] [Related]
2. Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas.
Davies M; Heller S; Sreenan S; Sapin H; Adetunji O; Tahbaz A; Vora J
Diabetes Care; 2013 May; 36(5):1368-76. PubMed ID: 23275363
[TBL] [Abstract][Full Text] [Related]
3. Dynamic risk factors associated with non-severe hypoglycemia in patients treated with insulin glargine or exenatide once weekly.
Paul SK; Maggs D; Klein K; Best JH
J Diabetes; 2015 Jan; 7(1):60-7. PubMed ID: 25168883
[TBL] [Abstract][Full Text] [Related]
4. Exenatide once weekly versus daily basal insulin as add-on treatment to metformin with or without a sulfonylurea: a retrospective pooled analysis in patients with poor glycemic control.
Grimm M; Li Y; Brunell SC; Blase E
Postgrad Med; 2013 Sep; 125(5):101-8. PubMed ID: 24113668
[TBL] [Abstract][Full Text] [Related]
5. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study.
Inagaki N; Atsumi Y; Oura T; Saito H; Imaoka T
Clin Ther; 2012 Sep; 34(9):1892-908.e1. PubMed ID: 22884767
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.
Diamant M; Nauck MA; Shaginian R; Malone JK; Cleall S; Reaney M; de Vries D; Hoogwerf BJ; MacConell L; Wolffenbuttel BH;
Diabetes Care; 2014 Oct; 37(10):2763-73. PubMed ID: 25011946
[TBL] [Abstract][Full Text] [Related]
8. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG;
Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722
[TBL] [Abstract][Full Text] [Related]
9. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes.
DeYoung MB; MacConell L; Sarin V; Trautmann M; Herbert P
Diabetes Technol Ther; 2011 Nov; 13(11):1145-54. PubMed ID: 21751887
[TBL] [Abstract][Full Text] [Related]
10. Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US.
Samyshkin Y; Guillermin AL; Best JH; Brunell SC; Lloyd A
J Med Econ; 2012; 15 Suppl 2():6-13. PubMed ID: 22793669
[TBL] [Abstract][Full Text] [Related]
11. Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland - subgroup data from a randomised multinational trial GWAA.
Matyjaszek-Matuszek B; Lenart-Lipińska M; Rogalska D; Nowakowski A;
Endokrynol Pol; 2013; 64(5):375-82. PubMed ID: 24186595
[TBL] [Abstract][Full Text] [Related]
12. Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals.
Meloni AR; DeYoung MB; Han J; Best JH; Grimm M
Cardiovasc Diabetol; 2013 Mar; 12():48. PubMed ID: 23522121
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus.
Levin PA; Mersey JH; Zhou S; Bromberger LA
Endocr Pract; 2012; 18(1):17-25. PubMed ID: 21742605
[TBL] [Abstract][Full Text] [Related]
14. Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications.
Pencek R; Brunell SC; Li Y; Hoogwerf BJ; Malone J
Postgrad Med; 2012 Jul; 124(4):33-40. PubMed ID: 22913892
[TBL] [Abstract][Full Text] [Related]
15. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
Buse JB; Bergenstal RM; Glass LC; Heilmann CR; Lewis MS; Kwan AY; Hoogwerf BJ; Rosenstock J
Ann Intern Med; 2011 Jan; 154(2):103-12. PubMed ID: 21138825
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.
Russell-Jones D; Cuddihy RM; Hanefeld M; Kumar A; González JG; Chan M; Wolka AM; Boardman MK;
Diabetes Care; 2012 Feb; 35(2):252-8. PubMed ID: 22210563
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m(2) in Spain.
Fonseca T; Clegg J; Caputo G; Norrbacka K; Dilla T; Alvarez M
J Med Econ; 2013 Jul; 16(7):926-38. PubMed ID: 23659201
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials.
Grimm M; Han J; Weaver C; Griffin P; Schulteis CT; Dong H; Malloy J
Postgrad Med; 2013 May; 125(3):47-57. PubMed ID: 23748506
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.
Malloy J; Meloni A; Han J
Postgrad Med; 2013 May; 125(3):58-67. PubMed ID: 23748507
[TBL] [Abstract][Full Text] [Related]
20. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.
Diamant M; Van Gaal L; Stranks S; Northrup J; Cao D; Taylor K; Trautmann M
Lancet; 2010 Jun; 375(9733):2234-43. PubMed ID: 20609969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]